Our researchers have shown the potential of a new gene therapy approach to silence human sensory neurons as a means of treating persistent pain. Many current drugs for chronic pain are highly addictive, which makes it important to discover new alternatives.
Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.
PAINCAST: Neuropathic Pain Unravelled, a creative podcast about living with long-term pain, is part of a ground-breaking four-year collaborative research project into neuropathic pain.
Researchers from the University of Oxford have found that a brief form of cognitive behavioural therapy (CBT) for insomnia, delivered by nurses in GP surgeries, significantly improves sleep and quality of life compared to sleep hygiene alone.
The work of Oxford University's Oxford Simulation, Teaching and Research team (OxSTaR) has been recognised by a Collaborative Award for Teaching Excellence (CATE).
Clinical scientists in Oxford have presented a new method of imaging of the retina that overcomes many of the drawbacks of the current standard way of diagnosing and monitoring retinal diseases like age-related macular degeneration (AMD).
In the midst of a global opioid epidemic, a team of scientists is exploring natural killer (NK) cells as an alternative treatment for neuropathic pain.
The Davies and Rinaldi laboratories led 'glitter-essence imaging', a craft-based engagement activity at Freeland Primary School Science Day on 17 March 2023 for Brain Awareness Week.
Oxford University has announced the winners of Beyond Boundaries, its science-inspired schools\u2019 art competition. Their work will be going on public display at Oxford University Museum of Natural History for all to see, from Friday 30 June \u2013 Monday 3 July 2023.
This is an annual event where we join together to celebrate the work of our Department, and this year we made the most of being able to meet up in person, in a new venue, and with an innovative programme.
A ground-breaking experimental medicine programme that will enable researchers to more rapidly screen potential drugs in people with motor neuron disease (MND, also known as ALS), is announced today on Global MND Awareness Day.
Beacon Therapeutics, a pioneering new biotech company, has launched with a mission to restore and improve the vision of patients with retinal diseases. The company is one of the most ambitious spinouts the University has been involved in to date, starting out with an impressive \u00a396 million ($118.5m) in funding, the biggest launch for any company including an Oxford spin-out programme.
The University of Oxford and Selvita (WSE: SLV), one of the largest contract research organisations in Europe, are collaborating on drug discovery in the area of Parkinson's disease
![\"Illustration](\"https://www.ndcn.ox.ac.uk/news/gene-therapy-opens-new-possibilities-for-treating-chronic-pain/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n